Abbott Articles
ARV price cuts agreed for Latin America
15 August 2005
NZ Pharmac gets budget boost, OKs new Rx uses
8 August 2005
Australian PBS adds 45 drugs, widens use for 28
8 August 2005
Abbott/Nephromics enter accord for preeclampsia test
8 August 2005
Stock Commentary - New York
25 July 2005
Abbott hires John Taylor for govt affairs post
25 July 2005
Japan stock market week to July 18
25 July 2005
BI's Flomax shows good AE profile
18 July 2005
Norwood Immunology on track for BMT trial
11 July 2005
Japan stock market week to July 4
11 July 2005
Merck & Co fails to delay first Vioxx trial
11 July 2005
Newer, pediatric, second-line ARVs "cost up to 12 times more than first-line drugs in LDCs"
11 July 2005
Abbott and Qiagen extend distribution deal
4 July 2005
Abbott UK: "growth of 70% in next five years"
27 June 2005
Humira boosts QoL in psoriatic arthritis
20 June 2005
Abbott's Humira/MTX: good long-term outcome
20 June 2005
Brazilian deputies OK patent-breaking bill
13 June 2005
Domantis: milestone under Abbott deal
13 June 2005
Stock Commentary - New York
6 June 2005
Qiagen to buy artus GmbH in $39M deal
6 June 2005
Xanthus' Xanafide sees good safety data
30 May 2005
Humira: strong results against Crohn's disease
30 May 2005
Abbott enrolls first patient in ZoMaxx study
30 May 2005
Pfizer's Celebrex gains from Bextra withdrawal
30 May 2005
Hospira launches in Canada
23 May 2005
Teva gets FDA OK for generic clarithromycin
23 May 2005
Final FDA approval for Teva's fenofibrate
23 May 2005
Japan stock market week to May 16
23 May 2005
Brazil slammed over HIV/AIDS drug patents
23 May 2005
Challenge to Australian pharmacy "closed shop"
16 May 2005
Texas sues 12 firms over drug prices
16 May 2005
Andrx reports 33% income rise
16 May 2005
FDA clears Abbott's Kaletra once daily
9 May 2005
Abbott files sNDA for Kaletra tablets
9 May 2005
Together Rx Access ads launched
27 April 2005
Stock Commentary - New York
25 April 2005
Japan stock market week to April 18
25 April 2005
Abbott submits StarClose for US FDA approval
18 April 2005
Stock Commentary - New York
11 April 2005
UK guide for industry on Rx access in DCs
4 April 2005
Australian pharma OKs 12.5% generic price cut
4 April 2005
Abbott gets leave of appeal on CAT royalty decision
28 March 2005
Brazil license request to HIV/AIDS drugmakers
28 March 2005
South Africa awards ARV drug tenders
14 March 2005
Donald Halbert becomes exec VP, R&D, at Iconix
7 March 2005
MedImmune and Abbott expand ex-US agreement
7 March 2005
Laura Schumacher promoted at Abbott Labs
28 February 2005
Abbot's Humira gives promising psoriasis results
28 February 2005
US FDA panel says COX-2s can be sold, OKs Vioxx' return to market?
28 February 2005
Fournier's 2004 drug sales boosted by US
28 February 2005
Abbott and Nihon Kohden in diagnostics deal
21 February 2005
Santarus wins payout against TAP
21 February 2005
Japan stock market week to February 14
21 February 2005
FDA accepts NDA for Abbott's Xinlay
21 February 2005
Strong 3rd-qtr for Takeda, as Actos and candesartan expand globally
21 February 2005
Australia/US FTA review mechanism principles
14 February 2005
Australia backtracks on 12.5% generic price cut
14 February 2005
Cambridge Antibody projects lower cash burn, break-even in 2007/8?
14 February 2005
Stock Commentary - Europe
7 February 2005
Abbott's RA drug Humira a potential therapy for Crohn's disease?
7 February 2005
Norwood gets FDA OK for Ph II BMT study
7 February 2005
Japan stock market week to January 24
31 January 2005
Australian drug price surcharge claim
31 January 2005
Highlights of pharmaceutical mergers and acquisitions in 2004
24 January 2005
Japan stock market week to January 17
24 January 2005
Icagen and Abbott renew drug discovery collaboration
24 January 2005
Industry cuts 275+ Rx prices for US uninsured under expanded Together Rx Access plan
17 January 2005
Stock Commentary - Europe
10 January 2005
Japan stock market three weeks to January 3
10 January 2005
Abbott submits Humira filings for RA
10 January 2005
S-P to pay $6M+ to Pa Medicaid program in Claritin pricing case
10 January 2005
CAT prevails in Humira royalty dispute with Abbott
10 January 2005
Abbott's Humira filed for new use in USA and EU
10 January 2005
Abbott issues 2005 outlook and confirms 2004 guidance
10 January 2005
FDA rates Lannett's levothyroxine AB
20 December 2004
Abbott files Xinlay NDA with FDA
20 December 2004
Australia: no generic price cuts till Feb
20 December 2004
Promising Ph II data for Abbott's ABT-874
22 November 2004
Eisai 1st-half sales on target, rising 5.3%
15 November 2004
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
